ClinicalTrials.gg
RecruitingNCT07410000Updated Nov 10, 2026

Ultrasound-Guided Quadro-Iliac Plane Block for Pain Management After Total Hip Arthroplasty

An interventional study of Quadro-Iliac Plane (QIP) Block and Sham Block in Pain Management and Total Hip Arthroplasty, sponsored by Bursa City Hospital. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Bursa City Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Nov 10, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This prospective, randomized, double-blind study evaluates the analgesic effectiveness of the ultrasound-guided Quadro-Iliac Plane (QIP) block in patients undergoing primary total hip arthroplasty. The QIP block is a recently described fascial plane block. Patients will be randomized to receive either a QIP block with local anesthetic or a sham block with saline. The primary outcome is 24-hour opioid consumption. Secondary outcomes include motor block, dermatomal sensory assessment, pain scores, rescue analgesic requirement, quality of recovery (QoR-15), and opioid-related side effects.

Read the detailed description

Total hip arthroplasty is associated with significant postoperative pain. The Quadro-Iliac Plane (QIP) block is a recently described fascial plane block targeting the area where the quadratus lumborum muscle attaches to the iliac crest and may provide more comprehensive analgesia. This study is designed as a prospective, randomized, double-blind clinical trial including patients aged 18-80 years with ASA physical status I-III undergoing elective primary total hip arthroplasty.

Patients will be randomized into two groups. The QIP group will receive an ultrasound-guided QIP block with 40 mL of 0.25% local anesthetic solution containing epinephrine, and the control group will receive a sham block with 40 mL of 0.9% NaCl using the same technique. The primary outcome is postoperative 24-hour opioid consumption. Secondary outcomes include motor block, and dermatomal sensory assessment, pain scores, quality of recovery (QoR-15), rescue analgesic requirement and opioid-related side effects

02

Conditions studied

  • Pain Management
  • Total Hip Arthroplasty

Keywords

  • Total Hip Arthroplasty
  • Postoperative Analgesia
  • Quadro-Iliac Plane Block
03

In context

Lead sponsor

Bursa City Hospital is the lead sponsor of 71 studies on the registry; 31 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (ASA) classification I-III
  • Age between 18 and 80 years
  • Patients scheduled for elective primary total hip arthroplasty

Exclusion criteria

Exclusion Criteria:

  • Refusal to participate in the study
  • Allergy to local anesthetics or opioids
  • Known or suspected coagulopathy
  • Infection at the injection site
  • History of previous hip surgery
  • Severe cardiovascular disease
  • Liver or kidney failure
  • Pregnancy, suspected pregnancy, or breastfeeding
  • Severe neurological or psychiatric disorder
  • Chronic opioid use
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Quadro-Iliac Plane (QIP) Block

    Participants in this arm will receive the standard analgesia protocol used for patients undergoing total hip arthroplasty. In addition to this standard regimen, an ultrasound-guided Quadro-Iliac Plane (QIP) block will be performed in the preoperative period with the patient in the lateral decubitus position. The technique aims to provide postoperative analgesia by achieving sensory blockade in the relevant dermatomal areas.

    Procedure: Quadro-Iliac Plane (QIP) Block

  • Placebo comparator
    Sham Block (Control)

    Participants in this arm will receive the standard analgesia protocol used for patients undergoing total hip arthroplasty. In addition to this standard regimen, a sham block will be performed using the same ultrasound-guided technique and patient positioning to mimic the block procedure without providing active regional anesthesia.

    Procedure: Sham Block

Interventions

  • ProcedureQuadro-Iliac Plane (QIP) Block

    An ultrasound-guided Quadro-Iliac Plane block performed in the preoperative period. At the level of the iliac crest, 40 mL of a solution containing 0.25% levobupivacaine and 5 µg/mL epinephrine is injected into the fascial plane between the erector spinae muscle and the quadratus lumborum muscle under aseptic conditions.

    Also known as: QIP Block

  • ProcedureSham Block

    A sham block performed using the same ultrasound-guided technique in the preoperative period. At the level of the iliac crest, 40 mL of 0.9% NaCl is injected into the fascial plane between the erector spinae muscle and the quadratus lumborum muscle under aseptic conditions.

    Also known as: Control Block

06

What researchers measure

Primary outcomes

  1. Postoperative 24-Hour Morphine PCA Consumption

    Total amount of morphine delivered by the patient-controlled analgesia (PCA) device during the first 24 hours after surgery, recorded in milligrams (mg).

    Time frame: Postoperative 24 hours

Secondary outcomes

  1. NRS Pain Scores at Rest and Movement

    Postoperative pain will be assessed using the Numeric Rating Scale (NRS), where 0 indicates no pain and 10 indicates the worst pain imaginable.

    Time frame: 2, 6, 12, 24, and 48 hours postoperatively

  2. QoR-15 Recovery Score

    The investigators will use the Turkish version of Quality of Recovery (QoR) / QoR-15 questionnaire. PART A How have you been feeling in the last 24 hours? (0 to 10, where: 0 = none of the time \[poor\] and 10 = all of the time \[excellent\]) Able to breathe easily Been able to enjoy food Feeling rested Have had a good sleep Able to look after personal toilet and hygiene unaided Able to communicate Getting support from hospital doctors and nurses Able to return to work or usual home activities Feeling comfortable and in control Having a feeling of general well-being PART B Have you had any of the following in the last 24 hours? (10 to 0, where: 10 = none of the time \[excellent\] and 0 = all of the time \[poor\]) Moderate pain Severe pain Nausea or vomiting Feeling worried or anxious Feeling sad or depressed \[Total score range: 0-150 points\]

    Time frame: QoR-15 Recovery Score will be evaluated at the postoperative 48th hour

  3. Lower Extremity Muscle Strength Score

    Postoperative lower extremity muscle strength will be assessed at the 6th postoperative hour using a 0-5 grading scale, where 0 indicates no muscle contraction and 5 indicates normal strength. The scale is defined as follows: 0 = no muscle contraction 1. = muscle contraction present without joint movement 2. = movement without overcoming gravity 3. = movement against gravity without resistance 4. = movement against partial resistance 5. = movement against full resistance (normal strength)

    Time frame: Postoperative 6th and 12th hours

  4. Rescue Analgesic Requirement

    Number of patients requiring rescue analgesia (IV meperidine 0.5 mg/kg) and total dose administered when NRS ≥ 4.

    Time frame: Postoperative 0-48 hours

  5. Opioid-Related Side Effects

    Opioid-related side effects will be assessed postoperatively Other opioid-related side effects, including pruritus, constipation, and somnolence, will be recorded as present or absent.

    Time frame: Postoperative 0-48 hours

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Gan TJ. Poorly controlled postoperative pain: prevalence, consequences, and prevention. J Pain Res. 2017 Sep 25;10:2287-2298. doi: 10.2147/JPR.S144066. eCollection 2017. PubMed 29026331 ↗
  • Carella M, Beck F, Piette N, Denys S, Kurth W, Lecoq JP, Bonhomme VL. Effect of suprainguinal fascia iliaca compartment block on postoperative opioid consumption and functional recovery in posterolateral-approached total hip arthroplasty: a single-blind randomized controlled trial. Reg Anesth Pain Med. 2022 Jun 15:rapm-2021-103427. doi: 10.1136/rapm-2021-103427. Online ahead of print. PubMed 35705263 ↗
  • Marrone F, Sorrentino T, Pullano C, Tulgar S. A novel and feasible option for perioperative analgesia in hip fractures surgery: quadro-iliac plane block. Minerva Anestesiol. 2025 Jun;91(6):592-595. doi: 10.23736/S0375-9393.25.18801-9. Epub 2025 Mar 27. No abstract available. PubMed 40145906 ↗
  • Tulgar S, Ciftci B, Ahiskalioglu A, Bilal B, Sakul BU, Girit M, Akin T, Narayanan M, Alici HA. Ultrasound guided quadro-iliac plane block: another novel fascial plane block. Pain Med. 2024 May 3;25(6):370-373. doi: 10.1093/pm/pnae018. PubMed 38459608 ↗
  • Selvi O, Azizoglu M, Temel G, Tulgar S, Chitneni A, Cinar EN, Ozer Z, Gurkan Y. Translation and Validation of the Turkish Version of the Quality of Postoperative Recovery Score QoR-15: A Multi-Centred Cohort Study. Turk J Anaesthesiol Reanim. 2022 Dec;50(6):443-448. doi: 10.5152/TJAR.2022.21417. PubMed 36511494 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Mar 2026 to primary completion in Nov 2026, 7 months.

Primary completion moved once since we started tracking on Sep 25, 2026: Feb 2027 → Nov 2026, on Nov 10, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2026
First posted
Feb 13, 2026
StartActual
Mar 16, 2026
Primary completionActual
Nov 9, 2026was Feb 2027
CompletionEst.
Mar 15, 2027
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Feb 15, 2027→Nov 9, 2026 (actual)
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Primary completion Feb 15, 2027→Nov 9, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07410000
Lead sponsor
Bursa City Hospital
Responsible party
Mursel Ekinci (Assoc Prof, Bursa City Hospital) — Principal investigator
First posted
Feb 13, 2026
Start date
Mar 16, 2026
Primary completion
Nov 9, 2026
Completion
Mar 15, 2027 (estimated)
Last update
Nov 10, 2026

Study contacts

Mursel Ekinci, Assoc prof,MD
Contact
drmurselekinci@gmail.com
+905067137596
Mustafa Dikici, MD
Contact
mus.dikici88@gmail.com
+905055346540

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion